Abstract
Objectives
Reported estimates of the risk of agranulocytosis associated with metamizol have varied by several orders of magnitude. We assessed this association in a large database for the surveillance of blood dyscrasias.
Methods
Since 1980, all laboratory units of haematology in a defined area (3.3–4.1×106 inhabitants) contribute to the ascertainment of all cases of agranulocytosis meeting strict diagnostic criteria. These cases of patients with agranulocytosis and sex-, age-, hospital- and date-matched controls were interviewed using a structured questionnaire about previous drug exposures, and relative risks were calculated for several categories of exposure to metamizol.
Results
After a total follow-up of 78.73×106 person-years, 273 community cases of agranulocytosis had been found—of which 96 were excluded for various reasons and 177 were included in the case-control analysis—and were compared with 586 matched controls. Thirty cases of agranulocytosis (16.9%) and nine controls (1.5%) had been exposed to metamizol during the week before the index day. The adjusted relative risk was 25.8 [95% confidence interval (CI), 8.4–79.1], and the attributable incidence was 0.56 (0.4–0.8) cases per million inhabitants and per year. The risk disappeared after more than 10 days since the last dose of metamizol, and it increased with duration of use. Those with agranulocytosis exposed to metamizol had taken the drug for longer periods than the exposed controls. Compared with the cases recently reported from Sweden, the duration of use of metamizol by our exposed cases was substantially shorter, and the use of concomitant medications potentially causing agranulocytosis was lower.
Discussion
In our milieu, agranulocytosis attributable to metamizol is rare. Geographical disparities in its risk estimate can be partly explained by differences in its patterns of use, in terms of dose, duration and concomitant medications.
Similar content being viewed by others
References
Kaufman DW, Kelly JP, Levy M, Shapiro S (1991) The drug etiology of agranulocytosis and aplastic anemia. Oxford University Press, New York
Kaufman DW, Kelly JP, Levy M, Shapiro S (1986) The drug etiology of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. JAMA 256:1749–1757
van der Klauw MM, Goudsmit R, Halie MR, van’t Veer MB, Herings RMC, Wilson JHP, Stricker BHCh (1999) A population-based case-cohort study of drug-associated agranulocytosis. Arch Intern Med 159:369–374
Maj S, Lis Y (2002) The incidence of metamizol sodium-induced agranulocytosis in Poland. J Int Med Res 30:488–495
Hedenmalm K, Spigset O (2002) Agranulocytosis and other blood dyscrasias associated with metamizol (metamizol). Eur J Clin Pharmacol 58:265–274
Ibáñez L, Juan J, Pérez E, Carné X, Laporte J-R (1991) Agranulocytosis associated with aprindine and other antiarrhythmic drugs: an epidemiological approach. Eur Heart J 12:639–641
Laporte JR, Capellà D, Juan J (1990) Agranulocytosis induced by cinepazide. Eur J Clin Pharmacol 38:387–388
Ibáñez L, Ballarín E, Pérez E, Vidal X, Capellà D, Laporte JR (2000) Agranulocytosis induced by pyrithyldione, a sedative hypnotic drug. Eur J Clin Pharmacol 55:761–764
Ibáñez L, Ballarín E, Vidal X, Laporte JR (2000) Agranulocytosis associated with calcium dobesilate. Clinical course and risk estimation with the case-control and the case-population approaches. Eur J Clin Pharmacol 56:763–767
International Agranulocytosis and Aplastic Anemia Study (1983) The design of a study of the drug etiology of agranulocytosis and aplastic anemia. Eur J Clin Pharmacol 24:833–836
Discombe G (1952) Agranulocytosis caused by amidopyrine: an avoidable cause of death. BMJ i:1270–1273
Huguley CM (1964) Agranulocytosis induced by dipyrone, a hazardous antipyretic and analgesic. JAMA 189:938–941
Palva IP, Mustala DO (1970) Drug induced agranulocytosis with special reference to aminophenazone. Acta Med Scand 187:109–115
Böttiger LE, Westerholm B (1973) Drug-induced blood dyscrasias in Sweden. BMJ iii:339–343
Varonos DD, Santamouris S, Karambali S (1979) The incidence of dipyrone induced agranulocytosis in Greece during 1975. J Int Med Res 7:564–568
Laporte JR, Carné X (1987) Blood dyscrasias and the relative safety of non-narcotic analgesics. Lancet i:809
Bäckstrom M, Hägg S, Mjörndal T, Dahlqvist R (2002) Utilization pattern of metamizol in northern Sweden and risk estimates of agranulocytosis. Pharmacoepidemiol Drug Saf 11:239–245
Capellà D, Laporte JR, Vidal X, Wiholm B-E, Bégaud B, Langman MJS, Rawlins M (1999) European network for the case-population surveillance of rare diseases (Euronet). A prospective feasibility study. Eur J Clin Pharmacol 53:299–302
Coordinating Centre (1999) A feasibility study of a European case-cohort surveillance network (EURONET) of serious ADRs to new pharmaceutical products. Euronet: final report. Contract n° BMH4-CT95-0467 (DG 12 – SSMA). DG XII, European Commission, Brussels
Herxheimer A, Yudkin JS (1984) Agranulocytosis and pyrazolone analgesics. Lancet i:730
Shapiro S (1984) Agranulocytosis and pyrazolone. Lancet i:1471.
Laporte J-R, Ibáñez L, Vidal X, Vendrell L, Leone R (2004) Upper gastrointestinal bleeding associated with the use of NSAIDs. Newer versus older agents. Drug Saf 27:411–420
Ibáñez L, Pérez E, Vidal X, Laporte J-R, The Grup d’Estudi Multicèntric d’Hepatotoxicitat Aguda de Barcelona (GEMHAB) (2002) Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J Hepatol 37:592–600
Böttiger LE, Westerholm B (1973) Acquired hemolytic anaemia. I. Incidence and aetiology. Acta Med Scand 193:223–226
Van der Klauw MM, Stricker B-HCh, Herings RMC, Cost WS, Valkenburg HA, Wilson JH (1993) A population based case-cohort study of drug-induced anaphylaxis. Br J Clin Pharmacol 35:400–408
Roujeau J-C, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F, Mockenhaupt M, Paoletti C, Shapiro S, Shear N, Schöpf E, Kaufman DW (1995) Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333:1600–1607
Laporte JR, Carné X, Vidal X, Moreno V, Juan J , The Catalan Countries Study on Upper Gastrointestinal Bleeding (1991) Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Lancet 337:85–89
Andrade SE, Martínez C, Walker AM (1998) Comparative safety evaluation of non-narcotic analgesics. J Clin Epidemiol 51:1357–1365
Acknowledgements
To the patients who participated in the study. The following haematologists collaborated in case reporting: E. Abella, E. Alonso, R. Ayats, C. Besses, A. Bosch, S. Brunet, N. Crespo, I. De Diego, A. Domingo, J. Estella, M. García, J.A. Hernández, A. Julià, R. López, P. Marín, F. Millà, J. Moll, T. Navarro, B. Nomdedéu, T. Olivé, L. Ortega, E. Pérez, J. Peris, A. Pineda, I. Roig, A. Solé, R. Soto and T. Toll. Dr. A. Julià (Service of Haematology, Hospital Vall d’Hebron) reviewed and confirmed the cases of agranulocytosis. Financial support was received from Hoechst AG (Frankfurt) from 1980 to 1986, and from Agencia Española del Medicamento (AEM, Spanish Medicines Agency) since 1998. Institut Català de la Salut provided personnel from 1987 to 2001. Since 2001, financial support was received from the AEM and from Aventis and Boehringer Ingelheim.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ibáñez, L., Vidal, X., Ballarín, E. et al. Agranulocytosis associated with dipyrone (metamizol). Eur J Clin Pharmacol 60, 821–829 (2005). https://doi.org/10.1007/s00228-004-0836-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-004-0836-y